28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
In a multivariate analysis, associations of MS4A6A (rs610932; odds ratio = 0.632, Bonferroni corrected P = .019) and CD33 (rs3865444; odds ratio = 1.492, Bonferroni corrected P = .017) with LOAD were replicated successfully. 5 key findings →
Participants: 1,224 Evidence: low
Full summary, score breakdown and related studies → Original source
Over the course of an individual’s lifetime, genomic alterations accumulate in somatic cells. 3 key findings →
Participants: 28 Evidence: low
Full summary, score breakdown and related studies → Original source
Recent advancements in computational approaches and neuroimaging techniques have refined our understanding of the precuneus. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Genome-wide association studies have identified a number of risk variants for Alzheimer’s disease implicated in inflammatory responses (Bettens et al., 2013); exome sequencing has revealed polymorphisms in the microglial receptor TREM2 gene as a rare but significant risk for Alzheimer’s disease (Guerreiro et al., 2013; Jonsson et al., 2013); and recently, the CD33 risk allele has been shown to inhibit microglial clearance of amyloid-β (Bradshaw et al., 2013; Griciuc et al., 2013). 5 key findings →
Participants: 39 Evidence: low
Full summary, score breakdown and related studies → Original source
These same brain areas were then assessed in a cohort of patients with Alzheimer’s disease versus a healthy older reference group, using a region of interest approach combined with standard structural (MRI), metabolic (fluorodeoxyglucose-PET) and amyloid ligand (florbetapir-PET) neuroimaging. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Initial studies suggested that IVIg contained antibodies against monomeric forms of Aβ 5. 5 key findings →
Design: open-label trial Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source
Type 2 diabetes and hyperglycemia with the resulting increase of glucose concentrations in the brain impair the outcome of ischemic stroke, and may increase the risk of developing Alzheimer's disease (AD). 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Sixty percent of the total patient group had baseline symptoms of agitation/aggression, delusions, or hallucinations on the NPI. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
The overall objective of the guideline is to provide up‐to‐date, evidence‐based recommendations for the management of bullous pemphigoid (BP). 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Seventy-one patients completed the trial. 5 key findings →
Participants: 36 Evidence: low
Full summary, score breakdown and related studies → Original source
We found no statistically significant differences in UPDRS scores, plasma BDNF levels or H(1)-MRS measures. 3 key findings →
Participants: 119 Evidence: low
Full summary, score breakdown and related studies → Original source
Thirty-four of the 37 patients were male with mean age at onset of 61.5 years for RBD and 68.1 years for cognitive decline. 5 key findings →
Participants: 37 Evidence: low
Full summary, score breakdown and related studies → Original source
We followed 65 patients with probable Alzheimer's disease, who were initially mildly to moderately impaired, with semiannual assessments of cognitive and functional performance for up to 4 years. 5 key findings →
Participants: 65 Evidence: low
Full summary, score breakdown and related studies → Original source
Neuropathologic etiologies of PPCD were Alzheimer disease (AD) (n = 13), AD plus Parkinson disease (n = 1), AD-Lewy body variant (n = 2), dementia with Lewy bodies plus progressive subcortical gliosis of Neumann (n = 1), corticobasal degeneration (n = 2), and prion-associated diseases: Creutzfeldt-Jakob disease (n = 1) and fatal familial insomnia (n = 1). 3 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep disruption, nightly restlessness, sundowning, and other circadian disturbances are frequently seen in Alzheimer's disease (AD) patients. 2 key findings →
Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source
Olfaction scores were lower in patients with mild cognitive impairment than in healthy comparison subjects. 5 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
The cause of progressive supranuclear palsy (PSP) is not known and has been little studied. 4 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source
Most patients came from the community (43% home without help and 42% home with help compared with 14% in assisted living and 1% in a nursing home). 5 key findings →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source
Although there was no difference in the microbial α-diversity among the three groups, patients with AD or MCI had increased β-diversity compared with healthy controls. 5 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
Missense mutations in the alpha-synuclein gene cause familial Parkinson's disease (PD), and alpha-synuclein is a major component of Lewy bodies (LBs) in sporadic PD, dementia with LBs (DLB), and the LB variant of Alzheimer's disease (AD). 3 key findings →
Participants: 65 Evidence: low
Full summary, score breakdown and related studies → Original source
In this study we used an in situ approach to identify the oxidized nucleosides 8-hydroxydeoxyguanosine (8OHdG) and 8-hydroxyguanosine (8OHG), markers of oxidative damage to DNA and RNA, respectively, in cases of Alzheimer's disease (AD). 1 key finding →
Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source
Caregivers in the combined family therapy and technology intervention experienced a significant reduction in depressive symptoms at 6 months. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Some studies have suggested that people with a high educational level have a lower risk of developing dementia compared to people with a low educational level. 4 key findings →
Participants: 1,022 Evidence: low
Full summary, score breakdown and related studies → Original source
Irritability, agitation, and aggression were documented in 81 patients (81%) an average of 10 months after diagnosis. 5 key findings →
Participants: 81 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The coexistence of cerebrovascular disease leading to deep white matter infarction and normal-pressure hydrocephalus has been noted previously in clinical studies, as both diseases can present with the triad of gait disturbance, dementia, and incontinence. 5 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →